​​Updated May 25, 2026

​

• NEW PUBLICATION: Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma DOI: https://doi.org/10.1158/0008-5472.CAN-25-0018 

​

• Featured by the MCW Cancer Center: Drugging the Undruggable: McFall Lab Unlocks New Treatments for KRAS-Driven Cancers.